SCHEMBL3717523

SCHEMBL3717523

CNc1cc(-c2cncc(-c3cnn(C4CCN(C(=O)OC(C)(C)C)CC4)c3)c2)cc(-c2ccccn2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 5/20 0.48
TNK2 Q07912 1/20 0.46
TTK P33981 2/20 0.45
FGFR1 P11362 2/20 0.45
FGFR2 P21802 2/20 0.45
FGFR4 P22455 2/20 0.45
FGFR3 P22607 2/20 0.45
KDR P35968 2/20 0.45
FLT3 P36888 2/20 0.45
USP30 Q70CQ3 1/20 0.44
CCNC P24863 1/20 0.42
CDK8 P49336 1/20 0.42
GPR119 Q8TDV5 3/20 0.41
LIPC P11150 1/20 0.41
RIPK2 O43353 1/20 0.41
DDB1 Q16531 1/20 0.41
CRBN Q96SW2 1/20 0.41
JAK2 O60674 1/20 0.40
JAK3 P52333 1/20 0.40
PTK2 Q05397 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3715497 0.84 IRAK4 (0.48) MET
SCHEMBL3722850 0.82 ALK (0.45) METTTKJAK2JAK3
SCHEMBL320089 0.77 CCNC (0.51) METTNK2TTKFGFR1FGFR2
SCHEMBL3724980 0.77 MET (0.42) METFGFR1FGFR2FGFR4FGFR3
SCHEMBL3728635 0.77 ALK (0.43) METTTKJAK2JAK3
SCHEMBL30701907 0.76 CCNC (0.51) METTNK2TTKFGFR1FGFR2
SCHEMBL320524 0.76 CCNC (0.46) METTNK2TTKFGFR1FGFR2
SCHEMBL3721843 0.76 ACVR1B (0.44) JAK2JAK3
SCHEMBL1653749 0.76 TNK2 (0.56) METTNK2FGFR1FGFR2FGFR4
SCHEMBL2330119 0.76 MET (0.47) METTNK2TTKFGFR1FGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2242742-B1 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2015-12-02 EP disclosed
US-8343966-B2 Organic compounds NOVARTIS AG (CH) 2013-01-01 US disclosed
EP-2242742-A2 ORGANIC COMPOUNDS Novartis AG (CH) 2010-10-27 EP disclosed
US-20090215776-A1 Organic compounds ADCOCK CLAIRE 2009-08-27 US disclosed
WO-2009087212-A2 PYRIDINE DERIVATIVES NOVARTIS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215776-A1 Organic compounds REN, RXFP1, MYLK MET 1544/4885TNK2 3198/4885TTK 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.